Skip to main content

Table 1 Relationship between clinical and biochemical characteristics and molecular groups of inflammation and fibrosis in infants with biliary atresia

From: Staging of biliary atresia at diagnosis by molecular profiling of the liver

Patient characteristic Inflammation group, N = 15 Fibrosis group, N = 26 Total, N = 41a P-valueb
Sex, N (%)     
   Female 6 (40) 12 (46) 18 (44) 0.8
   Male 9 (60) 14 (54) 23 (56)  
Race, N (%)     
   White 11 (73) 19 (73) 30 (73) 1.0
   Black 1 (7) 1 (4) 2 (5) 1.0
   Asian 2 (13) 1 (4) 3 (7) 0.5
   Other 1 (7) 5 (19) 6 (15) 0.6
Ethnicity, N (%)     
   Hispanic 1 (7) 1 (6) 5 (12) 0.6
   Nonhispanic 14 (93) 25 (94) 36 (88)  
Age in days, median (25-75%) 55 (46.3-63) 71 (54-80) 65 (50-75) <0.01
Clinical type     
   BASM N (%) 2 (13) 3 (12) 5 (12) 1.0
   Perinatal N (%) 13 (87) 23 (88) 36 (88)  
Mean CB at diagnosisc 4.9 ± 2.1 5.8 ± 2.4 5.5 ± 2.3 0.3
Mean ALT at diagnosisc 125 ± 83 154 ± 74 144 ± 78 0.3
Mean CB at 3 months after HPEc 1.7 ± 2.6 3.5 ± 5.3 2.8 ± 4.5 0.3
Weight Z-score at 6 months after HPEc -1.3 ± 1.1 -1.7 ± 1.2 -1.5 ± 1.2 0.4
Presence of cholangitis, N (%) 8 (53) 18 (72) 26 (63) 0.5
Presence of ascites, N (%) 4 (27) 12 (48) 16 (40) 0.3
  1. aSix patients from the cohort of 47 patients are not included because they were 'unclassified' by gene expression profiling (N = 4) or dropped off the study before 2 years of age (N = 2). bP-values denote levels of statistical differences between the inflammation and fibrosis groups. cMean ± standard deviation. ALT, alanine aminotransferases; BASM, biliary atresia splenic malformation (polysplenia or asplenia); CB, conjugated bilirubin; HPE, hepatoportoenterostomy.